RecruitingPhase 2NCT04732416
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
Studying Hyperinsulinemic hypoglycaemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hanmi Pharmaceutical Company Limited
- Intervention
- HM15136(drug)
- Enrollment
- 16 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2022 – 2025
Study locations (7)
- University of California Los Angeles, Los Angeles, California, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Otto-von-Guericke-Universitaet Magdeburg, Magdeburg, Germany
- Hadassah Medical Center (HMC), Jerusalem, Israel
- Asan Medical Center, Seoul, South Korea
- Great Ormond Street Hospital (GOSH) for Children NHS Foundation Trust, London, United Kingdom
- Central Manchester University Hospitals NHS Foundation Trust - Royal Manchester Children's Hospital - Centre for Paediatrics and Child Health, Manchester, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04732416 on ClinicalTrials.govOther trials for Hyperinsulinemic hypoglycaemia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT06208215RZ358 Treatment for Congenital HyperinsulinismRezolute
- ACTIVE NOT RECRUITINGPHASE3NCT03941236Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital HyperinsulinismZealand Pharma
- RECRUITINGPHASE2NCT0420560418FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital HyperinsulinismMiguel Pampaloni
- RECRUITINGPHASE1NCT02021604Fluorodopa F 18 in Congenital Hyperinsulinism and InsulinomaCook Children's Health Care System